Biocartis 2018 results, 2019 outlook and menu strategy

28 February 2019

Today's presenters

Simone Marticke
Strategy Lead

Ewoud Welten
Chief Financial Officer

Herman Verrelst
Chief Executive Officer

BIOCARTIS

NOTICES AND WARNINGS

This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. It is not a prospectus or offering memorandum.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The Company's securities have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.

Agenda

1. 2018 business review
2. Idylla™ menu strategy
3. 2019 outlook
4. Q&A

2018 business review

Fully automated molecular testing with Idylla™



Superior sensitivity and ease-of-use, combined with sample to result turnaround time of 90 to 150* minutes

* Based on turnaround times of current on-market oncology tests

Platform and consumable driven business model



Key drivers
- Commercial footprint
- Commercialization partnerships

Key drivers
- Menu of tests
- Regulatory registrations

Key drivers
- Reimbursement
- Competitive advantage

Gross margin driven by
- Volume
- Manufacturing automation

BIOCARTIS

Key messages FY 2018 results

Installed base	Growth of installed base to over 970 instruments
Cartridge volume	133k Idylla™ cartridges, year-over-year increase of approx. 87%
Product revenues	Increased year-over-year with 46% to EUR 18.8m
Total operating income	Increased year-over-year with 24% to EUR 28.7m
Cash position	EUR 64m per end 2018
Test menu	Promising initial market adoption of the Idylla™ MSI Test[2]
Partnerships	Expansion partnership with Genomic Health and new collaboration with AstraZeneca
Geographical expansion	Successful first commercialization year in US, go-to market strategies established for China and Japan

BIOCARTIS

1 As of date of this announcement
2 Launched as CE-IVD on 28 February 2019

Strong continued placements & volume growth

Installed base (in # instruments)

- 326 instruments added in 2018, exceeding latest guidance of 300
- Majority of placements realized in European and US markets
- Installed base milestone of 1,000 instruments crossed early 2019

Commercial cartridge volume (x 1,000)



- Commercial cartridge volume of approx. 133k, in line with the latest 2018 guidance of 130k – 135k cartridges
- Year-over-year increase of approx. 87%, Europe followed by RoW[1] contributed most to the absolute volume growth

1 RoW = Rest of the World. RoW is defined as the world excluding European direct markets, US, China and Japan

Delivering solid performance across markets

Europe

- Increase in installed base above expectation
- Strong ramp-up of commercial cartridge volumes due to:
  - Increased Idylla™ usage in first line testing
  - Strong overall contribution from pharmaceutical collaborations
  - Launch Idylla™ MSI Test[1]

US

- First full commercialization year
- Realization of promising initial US installed base driven by:
  - Platform adoption at high profile customers such as

Memorial Sloan Kettering Cancer Center

Dartmouth-Hitchcock MEDICAL CENTER

  - Publication of several US Idylla™ performance studies of which 8 were presented at AMP[2]

RoW[3]

- Strong ramp-up in cartridge volumes driven by:
  - 57 new market authorizations for Idylla™ products across 18 geographies
  - Strategic focus on geographies that are of interest to pharmaceutical partners

BIOCARTIS

1 Launched as CE-IVD on 28 February 2019
2 Association for Molecular Pathology Conference, 1-3 November 2018, Texas, US
3 RoW = Rest of the World. RoW is defined as the world excluding European direct markets, US, China and Japan

Product revenues increased with 46% in 2018

Breakdown product revenues (in EUR 1,000)

By product	2018	2017
Idylla™ System sales	4,185	4,620
Idylla™ Cartridge sales	14,658	8,316
Product sales revenue	**18,843**	**12,936**

By type	2018	2017
Commercial revenue	17,843	12,748
R&D revenue	1,000	187
Product sales revenue	**18,843**	**12,936**

Breakdown total operating income

In EUR 1,000	2018	2017
Product sales revenue	18,843	12,936
Collaboration revenue	8,329	7,739
Service revenue	639	282
Total revenue	**27,811**	**20,957**
Grants and other income	840	2,153
Total operating income	**28,651**	**23,110**

BIOCARTIS

2018 operating result of EUR -47m

Condensed income statement

In EUR 1,000	2018	2017
Total operating income	**28,651**	**23,110**
COGS	(15,349)	(8,673)
R&D expenses	(36,842)	(39,594)
S&M expenses	(15,349)	(11,600)
G&A expenses	(7,971)	(6,832)
Total operating expenses	**(75,511)**	**(66,699)**
Operating result	**(46,860)**	**(43,589)**
Net financial result	(1,402)	(1,736)
Income taxes	109	3,365
Net result	**(48,153)**	**(41,960)**

Breakdown operating expenses





Cash position of EUR 64m end of 2018

Condensed cash flow statement

In EUR 1,000	2018	2017
Result for the period	**(48,153)**	**(41,960)**
Depreciation and amortization	4,273	5,096
Impairment losses	3,456	0
Working capital changes	(3,797)	(2,841)
Other adjustments	2,228	(1,700)
CF operating activities	**(41,993)**	**(41,405)**
CF investing activities	(5,820)	(4,320)
CF financing activities	(1,508)	75,256
Total net cash flow	**(49,320)**	**29,531**
Cash and cash equivalents[1]	**63,539**	**112,765**
Financial debt	35,335	35,388

1. Including EUR 1.2 million restricted cash related to KBC Lease financing

Remarks

- Cash flow from operating activities slightly lower as result of:
  - A lower net result for 2018
  - Increased investments in working capital
  - Increased (non-cash) adjustments in 2018 due to impairment losses and an one-off income statement impact in 2017 related to a tax adjustment
- Cash flow from investing activities:
  - Consists of capitalization of Idylla™ instrumentation as well as investments in laboratory and manufacturing equipment
  - Note: 2018 investments for cartridge manufacturing expansion were directly paid for via lease financing
- Cash flow from financing activities consisted of repayments on borrowings partially offset by proceeds from the exercise of warrants
- Net cash flow of EUR -49.3m, resulting in a cash position per year-end of EUR 64m. Note: due to the capital raise in January 2019, the cash position as per end January 2019 amounted to over EUR 110m (unaudited figure)

Successful EUR 55.5m capital raise in January 2019

Placement details

- Gross proceeds of EUR 55.5m by means of a private placement via an accelerated bookbuild offering
- Raised from high quality institutional investors, both existing and new international investors, from both Europe and the US
- New shares represent approx. 9.73% of the Company's share capital immediately prior to the capital raise
- One of the first equity capital markets transaction of the European Life Sciences and Healthcare industry in 2019

Ewoud Welten, Chief Financial Officer of Biocartis, commented:

"Today's oversubscribed private placement further strengthens the capitalisation of Biocartis. We are pleased to see that even in challenging market conditions, both existing and new international institutional investors continue to support Biocartis in the further execution of its business plan. That is a great motivator to our teams and partners as well as a strong recognition of the progress that Biocartis has made over the last year."

BIOCARTIS

Go-to market strategies in place for China & Japan

Chinese go-to market strategy

- Joint venture established with Wondfo for Chinese market
- Chinese MDx market one of fastest growing in the world[2]
- Wondfo (SHE:300482) is a fast growing diagnostics leader in China with focus on POC[1] testing, listed on Shenzhen Exchange (current market capitalization of USD ~1.3bn) with revenues in 2017 of ~ USD 160m
- Joint venture structure: 50%-50% ownership. Capital commitment of EUR 14m, split between parties and over several tranches
- Focus on local manufacturing, commercialization & registration with Chinese Regulatory Authorities of existing Idylla™ oncology tests

Japanese go-to market strategy

- Commercialization agreement with Nichirei Bioscience for Japanese market
- Japanse MDx market is one of the largest in the world, representing around 10% of global MDx market[1]
- Part of Nichirei Corporation (TYO: 2871), a holding company with an annual turnover of ~¥ 550 billion[2]
- Nichirei Bioscience to seek regulatory approval of Idylla™ platform and its oncology tests with Japanese Ministry of Health, Labor and Welfare
- Upon successful registration, Nichirei Bioscience's sales force will distribute the Idylla™ platform across its commercial network of approx. 2,000 pathology laboratories in Japan

BIOCARTIS

1 Point of Care. 2 Source: DataMintelligence, "Global Molecular Diagnostics Market 2018-2025"

1 Source: MarketsandMarkets, 2015. 2 Source: Nichirei Bioscience website and company information

Expansion of strategic collaboration with Genomic Health LIFE, CHANGING.

Background collaboration

- Focused on exclusive test development of proprietary Genomic Health tests on the Idylla™ platform
- Aimed at accelerating adoption and market access around the world of Genomic Health's tests
- First test to be developed on Idylla™ is the Oncotype DX Breast Recurrence Score® test, second test is the Oncotype DX Genomic Prostate Score® Test

Background Genomic Health

- A leading provider of genomic-based diagnostic tests in cancer with revenues of USD 377m in 2017
- Based in California (US) and listed on NASDAQ (GHDX) with a market cap of approx. USD 2.97bn
- On-market tests for breast, prostate and colon cancer, currently offered through own service laboratories

Oncotype DX Breast Recurrence Score® Test

- Examines the activity of 21 genes in a patient's breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease.
- Only test proven to predict chemotherapy benefit
- Included in all major cancer guidelines worldwide and is now considered standard of care for early-stage breast cancer.

Oncotype DX Genomic Prostate Score® Test

- Examines the activity of 17 genes in a patient's prostate biopsy sample to provide information on the aggressiveness of their individual disease
- Predicts risk of metastasis and helps to make better informed & more personalized treatment decisions
- Has been validated in > 4,500 patients, which is described in 18 publications

BIOCARTIS

Source: Company website and financial reporting Genomic Health

New pharma collaboration with AstraZeneca aimed at faster lung cancer biomarker results

Partnership details

- AstraZeneca is a global science-led biopharmaceutical company (LON: AZN)
- Agreement announced on 29 November 2018
- A prospective lung cancer study with the Idylla™ EGFR Mutation Test (CE-IVD) will be conducted in selected European countries, aimed at demonstrating how the unique features of the Idylla™ platform can overcome current complexity and long turnaround time for lung cancer patients by delivering accurate biomarker results faster and easier
- Study will be initiated at more than a dozen sites in Belgium, France, Germany and Italy

Background

- Lung cancer is most common cancer worldwide, contributing for 13% of all cancer types[1]
- In total, 85% of lung cancers are non-small cell lung cancers (NSCLC)[2]. Many lung cancers are driven by mutations in the epidermal growth factor receptor (EGFR), which occur in 10-15% of NSCLC patients in the US and the EU, and 30-40% of NSCLC patients in Asia[3]
- Current molecular testing of lung cancer samples is complex, also because obtaining high quality tissue samples is difficult. Results can take up to several weeks[4], often because many laboratories do not have the necessary infrastructure to perform complex tests and need to send out their samples

BIOCARTIS

1 Navani et al., Lancet Respir Med (2015). 2 American Cancer Society. Global Cancer Facts & Figures 2nd Edition (2011). 3 Website AstraZeneca. 4 Neal I. Lindeman et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2014)

Launch Idylla™ CE-IVD MSI Test

Background MSI

- MSI is the abbreviation of Micro Satellite Instability
- MSI is the result of inactivation of the body's so-called DNA mismatch repair (MMR) system. Consequently, errors that normally spontaneously occur during DNA replication are no longer corrected, contributing to tumor growth and evolution
- MSI testing is included in international guidelines for colorectal cancer, but is present in several other tumor types as well, such as gastric & endometrial cancer
- MSI is an independent factor that may predict a patient's response to certain immunotherapies

The Idylla™ MSI Test[1]

- Includes novel set of 7 MSI biomarkers[5], exclusively licensed to Biocartis[2] in 2013
- Unique characteristics:
  - Fully automated
  - Fast and accurate information on MSI status in colorectal cancer directly from FFPE tissue without the need for matched normal samples[3]
  - High concordance (> 97%) and lower failure rates compared to standard methods[3]
  - No need for paired normal tissue testing
  - Unbiased results reporting for a variety of cancer types independent of ethnicities[3]
- Expected to overcome drawbacks of conventional MSI testing, making MSI testing available to a larger patient population

Key addition to Biocartis' colorectal cancer menu

1 The Idylla™ MSI Test was launched as a CE-IVD marked test on 28 February 2019. 2 From VIB, the life sciences research institute in Flanders (Belgium), and originated from the research of the group of Prof. Diether Lambrechts (VIB-KU Leuven, Belgium). 3 Clinical Performance Study showed 99,7% concordance for MSI testing vs Promega (unpublished data); De Craene B. et al. Annals of Oncology (2017) 28 (suppl_5): v209-v268; De Craene et al. J Clin Oncol 36, 2018 (suppl; abstr e15639)>. 4 FFPE = formalin fixed, paraffin embedded. 5 Consisting of short homopolymers located in the ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2 genes.

High volume second cartridge manufacturing line

- Located in Mechelen (Belgium), providing an additional annual capacity of over 1,000,000 cartridges
- Fully automated assembly workstations (versus a semi-automated on first line with an annual capacity of over 200k cartridges)
- Plastic parts manufactured with new multi-cavity moulds (versus single cavity on first line)
- Operational since end of 2018
- Key driver in further reduction of cartridge unit costs

Strengthening of management team

Piet Houwen
Chief Operating Officer

Responsibility	• Manufacturing and supply chain • Cross-company initiatives and organizational development
Background	• + 25 years experience in various operational and general management roles • Strong track record in manufacturing, process engineering, project and people management • Was Chief Operations Officer at Ablynx and held global roles for Sanofi/Genzyme and Janssen Pharmaceuticals • Holds a Master's Degree in Mechanical Engineering from the Delft University of Technology (The Netherlands)

BIOCARTIS

Idylla™ test menu & strategy update

Uniquely positioned in attractive oncology MDx market

Fast growing market

Onco MDx

- Represents 19% of the USD 6.5bn total MDx market in 2016[1]
- Fastest growing segment in MDx, expected to grow 26% per annum (doubling of market) to 2020[2]

Key growth drivers

- Global incidence ~18.1bn; growing at ~2.5% per annum[3]
- Increased need for MDx testing:
  - Broader availability of targeted therapies
  - Significant clinical pipeline targeted therapies: in 2015, >800 cancer treatments were in development in the US[4], ~70% has potential to be personalized medicines[5]
  - Addition of new application areas: immuno-oncology, liquid biopsy testing, etc.
- Growth of decentralized market (i.e. under-penetrated customer potential)

Idylla™ unique selling points

1. Ability to combine advantages of point-of-care testing with performance of lab reference testing: enabling MDx in virtually any lab setting
2. Reduction of time-to-result from weeks to hours
3. Sample-to-result (i.e. full automation) capabilities for:
   - Solid biopsies: FFPE[6]*, FNA[7]^, fresh samples^
   - Liquid biopsies: Plasma*, whole blood^, urine^

1. MarketsandMarkets, 2017. 2. Berenberg research. 3. Globocan 2018, Estimated cancer incidence, mortality and prevalence worldwide, WHO International Agency for Research on Cancer. 4. PhRMA, "Medicines in Development for Cancer," September 2015, http://phrma.org/sites/default/files/pdf/oncology-report-2015.pdf; American Association for Cancer Research. 5. PhRMA, Oncology Report 2015. 6: FFPE = Formalin Fixed Paraffin Embedded. 7: FNA = Fine Needle Aspirates. * Validated sample type. ^ Research Use Only.

Market trends drive oncology menu strategy

Targeted therapies

- Therapy selection driven by specific cancer mutations
- Significant pipeline of new targeted therapies across cancer types
- Examples
  - Zelboraf®[1] (BRAF)
  - Tagrisso®[2] (EGFR)
  - Erbitux®[3] (RAS)
  - Vectibix®[4] (RAS)

Pan-cancer therapies



- Therapy selection driven by genetics rather than location of the tumor
- Allows therapy use across multiple cancer types
- Positive impact on underlying test volumes
- Examples
  - Vitrakvi®[5]
  - Keytruda®[6]

Gene signatures

- MDx tests that target applications beyond therapy selection, e.g.:
  - Cancer risk
  - Prognosis
- Often high value once validated and clinical value demonstrated
  - Critical information for medical decision-making

Immuno-oncology



- 'Fifth pillar' of cancer treatment
- Consists of several therapeutic classes, e.g.:
  - Immune checkpoint inhibitors
  - Cell and viral therapies
  - Vaccines
- High unmet need for underlying clinical testing

Liquid biopsy



- Assess tumor information via liquid samples
- Clinical value increasingly demonstrated
- Front-runner applications:
  - Therapy selection
  - On-therapy monitoring
  - Post-treatment Minimal Residual Disease ('MRD')

1. Marketed by Roche. 2 Marketed by AstraZeneca. 3. Marketed by Merck KGaA and Eli Lilly. 4. Marketed by Amgen. 5. Marketed by Bayer (licensed from Eli Lilly's Loxo). 6. Marketed by Merck.

Building blocks Idylla™ menu expansion strategy



Targeted therapies: towards actionable 2-cartridge menus and pan-cancer applications

Cancer-specific applications

2-cartridge menus for current cancer markets

- Enhanced development capabilities allow for higher number of targets in one Idylla™ cartridge
- Opportunity to offer actionable 1st line menus based on two Idylla™ cartridges only:

CRC[1] menu
1. KRAS/NRAS/BRAF
2. MSI

Lung menu
1. EGFR/BRAF+ (DNA-based)
2. GeneFusion (RNA-based)

New areas

- Development of new tests for additional cancer types e.g.:
  - Breast cancer
  - Gastric cancers
  - Hematological cancers
- Validation existing menu for additional sample types

Pan-cancer applications

- Core tests of cancer-specific menu are applicable for pan-cancer applications



Idylla™ cartridge
- KRAS/NRAS/BRAF
- MSI
- GeneFusion (NTRK)

Select potential applications
- Breast, endometrial, cervical
- Gastric, prostate, endometrial
- Gastro-intestinal, breast

Comprehensive actionable 1st-line menu in 2-cartridge format allows for higher market shares and gross margins

Efficient access to pan-cancer setting (validation of existing menu)

1. CRC = colorectal cancer.

Immunotherapy: towards menu serving major therapy classes

Idylla™ addressable immunotherapy segments

Immune checkpoint inhibitors

Prevent tumor from hiding from the immune system

- **Immune cells can fight** cancer
- **Cancers can hide** from immune cells
- Immune checkpoint inhibitors such as **Keytruda®**[1] prevent this hiding
- Such inhibitors often act **pan-cancer**



Cell therapy

Deploy immune cells designed to fight cancer

- Immune cells can be specifically **selected or engineered to fight** cancer
- To date, cell therapies have proven successful in **hematological** cancers
- Clinical trials ongoing also for **solid** cancers



Idylla™ for immune checkpoint inhibitors

Idylla™ MSI test

- May be validated for immunotherapy (i.e. immune checkpoint inhibitors) selection
- Initial focus on CRC immunotherapy
- Pan-cancer validation in the future

Idylla™ for both major therapeutic classes

Idylla™ Hot-Cold signature

- Is the immune system already fighting this cancer? Does it need to be enabled?

Idylla™ immunotherapy resistance test

- Is the tumor resistant to immunotherapy?

Idylla™ for cell therapy

Idylla™ test(s) for patient management

- Cell therapies are highly successful
- Therapy cost (e.g., hospitalization) and side effects create high need for rapid patient management around treatment

Growth in emerging therapeutic areas. Address testing needs of major immuno-therapies and leverage menu toward pan-cancer applications

1. Marketed by Merck.

Monitoring: liquid biopsy testing for on- and post-therapy monitoring

Liquid biopsy testing

- Access genetic tumor information via liquid samples:
  - Blood
  - Urine
  - Saliva
- Advantages over solid biopsy testing
  - Less invasive
  - Less expensive
  - Less sampling bias
  - More repeatable
  - Real-time mutation status
- Improved detection of low burden disease
  - Earlier and more accurate than current protein tests; earlier than imaging
  - Advantage for MRD[1], recurrence monitoring

Idylla™ liquid biopsy and monitoring menu

Cancer care continuum

Pre-diagnosis	• Inherited risk • Screening / early detection	
Diagnosis		
Pre-therapy	• Prognostics / stratification • Therapy selection	1
Treatment Start		
On-therapy	• Response monitoring • Resistance monitoring	2
Treatment Stop		
Post-therapy	• Post-therapy MRD[1] • Recurrence monitoring	2 3
Relapse		
Recurrence	• Therapy selection • Recurrence management	1

Menu focus

1 Therapy selection
- Liquid biopsies **complement solid biopsy** menu
- Focus: if **tissue not available** at diagnosis or at progression

2 Response monitoring and post-therapy MRD[1]
- **Focus**: applications that **require Idylla™ speed** and are backed by growing evidence of **clinical utility**:
  - On-therapy monitoring
  - Post-treatment MRD[1]
- Population: **Mid and late stage** patients across most cancer types

3 Recurrence monitoring
- Focus: on **hematological** cancers (e.g., CML[2]) as these are **established markets** (i.e. guidelines inclusion)
- Population: long-term therapy and recurrence monitoring

A high volume menu for repeat-testing applications that require Idylla™'s unmatched turn-around-time. Address testing needs across early and late stage cancers for a range of major cancer treatments. Access new customer base: hemato-oncologists and blood testing laboratories

1. MRD = Minimal Residual Disease. 2. CML = Chronic Myeloid Leukemia.

Gene signatures: high value and volume menu developed by partners

Market landscape

- Growing number of tests
  - Driven by genomic discovery and validation efforts over past decade
- Broad range of testing applications
  - Prognostic, risk stratification, screening tests, etc.
  - Tests are generally cancer-specific
- Diverse cancers and sample types
  - On-market or in development for many solid and hematological cancers
  - Solid & liquid samples

Test selection criteria

- Focus on oncology tests
- Clinically validated content
  - Increases barrier to entry for competitors
- High clinical utility and reimbursement
  - Provides attractive pricing and fast market adoption
- High volume applications
  - Large addressable population
  - High market share potential
  - Repeat testing

Idylla™ opportunity

- Additional cancer franchises
  - Complementary menu (e.g. breast cancer)
- Expansion into new customer segments
  - General oncology
  - Oncology sub-specialties within urology, dermatology, hematology…
- Broader commercial footprint
  - Commercialization supported by sales network partner
- Development mainly partner-funded

Example collaboration Genomic Health

Genomic Health LIFE. CHANGING.

- Market leader in breast, urology cancer

- Biocartis development partner
  - ✓ Clinically validated
  - ✓ High reimbursement
  - ✓ Attractive volumes

- Breast: launch 2020
- Urology franchise opportunity
  - Initial focus on prostate cancer

Complementary menu with proprietary high value and volume tests with a focus on existing and potentially additional customer segments

BIOCARTIS

Idylla™ addressable market potential

Biocartis owned tests

Partner owned

ANNUAL VOLUME POTENTIAL

MONITORING
- Therapy response & MRD[5]
- Recurrence monitoring

10m to 15m[+1]

IMMUNO-THERAPY
- MSI
- Hot-Cold signatures
- Resistance testing
- Cell therapy management

4m to 5m[+2]

TARGETED THERAPIES
- 2-cartridge menus for CRC and lung
- Pan-cancer applications
- Additional cancer types

3m to 4m[+3]

PROPRIETARY GENOMIC SIGNATURES
- Establish breast franchise
- Urology
- New cancer types & customer segments

1m to 5m[+4]

Short-term | Mid-term | Long-term

+ Depicts annual long term addressable Idylla™ cartridge volume potential. Based on management estimates. Focused on Europe, US and Japan (excluding China and RoW). For indicative purposes only. 1. Based on incidence / prevalence, potential eligibility (e.g., according to tumor stage and treatment) and # tests / patient. 2. Based on incidence and current / potential guideline testing eligibility for cancer types where immune checkpoint inhibitors and cell therapies are most relevant. 3. Based on incidence and current / anticipated cancer guidelines for CRC, lung, and skin cancer. 4. Based on current partner content collaborations and addition of new content that could benefit from Idylla™ dependent on partnerships. 5. MRD = Minimal Residual Disease

2019 outlook

Guidance 2019

Targeting installed base growth in 2019 of 350 new instrument placements, bringing the total installed base to over 1,300 Idylla™ instruments by year-end

Targeting a commercial volume of 210k-225k Idylla™ cartridges in 2019, representing a year-over-year increase of around 60%-70%

Targeted cash position in the range of EUR 55m – EUR 65m by 2019 year end, excluding drawdowns on the Company's multiple purpose credit facility.

Short term menu outlook (selection)

Area	Test	Timing
Colorectal cancer	• CE-marking Idylla™ MSI Assay	• Q1 2019 √
	• US FDA 510(k) submission Idylla™ MSI Test	• 2020
	• Submission of Idylla™ RAS PMA[1] documentation with US FDA	• 2020
Lung cancer	• Launch Idylla™ ctEGFR Assay (RUO[2])	• Mid-2019
	• Launch Idylla™ GeneFusion Panel	• 2020
Breast cancer	• Start European validation studies Idylla™ Oncotype DXi IVD Breast Recurrence Score™ test	• H2 2019
	• Launch of the Idylla™ Oncotype DXi IVD Breast Recurrence Score™ test in Europe	• 2020

1 PMA = Pre-Market Approval
2 RUO = Research Use Only, not for use in diagnostic procedures

Financial calendar 2019

• Publication 2018 annual report	4 April 2019
• Q1 2019 Business Update	25 April 2019
• Annual General Meeting	10 May 2019
• H1 2019 results	5 September 2019
• Q3 2019 Business Update	14 November 2019

BIOCARTIS

Q&A

BIOCARTIS